Arcus falls after co and Gilead scrap late-stage trial of cancer drug combo

Arcus Biosciences

12/12/2025 13:47

** Shares of drug developer Arcus Biosciences RCUS.N fall 8.5% to $23 premarket

** Co says it and Gilead GILD.O will stop a late-stage study testing their experimental cancer drug combination in patients with advanced stomach and esophageal cancers after it failed to show a survival benefit

** An interim analysis showed the combination of GILD's domvanalimab and RCUS' zimberelimab with chemotherapy did not improve overall survival compared to Bristol Myers Squibb's BMY.N nivolumab and chemotherapy

** Up to last close, stock had risen 68.8% YTD

 (Reporting by Puyaan Singh in Bengaluru)

 ((Puyaan.Singh@thomsonreuters.com;))